Remibrutinib Treatment Improves Quality of Life in Patients with Chronic Spontaneous Urticaria

Marcus Maurer,Ana Giménez-Arnau,Vipul Jain,Jeffrey Tillinghast, Alberto Tolcachier,Simon Nigen, Koremasa Hayam,Karine Lheritier,Pauline Walsh,Sibylle Haemmerle

The Journal of Allergy and Clinical Immunology（2022）

引用 5|浏览4

暂无评分

摘要

New therapies for chronic spontaneous urticaria (CSU) are needed as current treatments often inadequately control symptoms that impact patients’ quality of life (QoL). Remibrutinib is a Bruton’s tyrosine kinase (BTK) inhibitor that leads to blockade of mast cells and basophil activation, which is associated with CSU pathogenesis.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要